LIVIVO - Search results -

Search results

Result 1 - 10 of total 73

Search options

Book ; Online ; E-Book: Brain tumors

Mohile, Nimish A. / Thomas, Alissa A.

a pocket guide

2023

Abstract: This concise book serves as a practical primer for the care of patients with primary brain tumors. Divided into two major sections, the first provides chapters with key information for each major brain tumor type. This includes basic information about ... ...

Author's details	Nimish A. Mohile, Alissa A. Thomas editors
Abstract	This concise book serves as a practical primer for the care of patients with primary brain tumors. Divided into two major sections, the first provides chapters with key information for each major brain tumor type. This includes basic information about etiology, epidemiology, clinical features, pathology, imaging, diagnostic workup, and treatment. The second section of the book features chapters that delve into supportive care management with specifics about management for each of the major conditions. This includes tumor-related epilepsy, venous thromboembolism in brain tumor patients, and corticosteroid management and toxicity. Detailed and clinically-focused information about chemotherapy regimens, dosing, monitoring, management of toxicities and patient education are also provided. Brain Tumors is a quick resource in the inpatient setting or in the clinic and educational resource to help new providers in the neuro-oncology field with the accumulated knowledge of clinicians with practical experience. .
Keywords	Neurology ; Internal medicine
Language	English
Size	1 Online-Ressource (VI, 292 Seiten), Illustrationen, Diagramme
Publisher	Springer
Publishing place	Cham
Publishing country	Switzerland
Document type	Book ; Online ; E-Book
Remark	Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
HBZ-ID	HT030619793
ISBN	978-3-031-41413-8 ; 9783031414121 ; 3-031-41413-6 ; 3031414128
DOI	10.1007/978-3-031-41413-8
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Full text online

Accessible to users with ZB MED library card

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Tele-neuro-oncology: Current Practices and Future Directions.

Wasilewski, Andrea / Mohile, Nimish

Current oncology reports

2022 Volume 24, Issue 1, Page(s) 99–103

Abstract: Purpose of review: The purpose of this review is to describe the current state of telemedicine within neuro-oncology. This article will address the development of tele-neuro-oncology over time with a focus on current use and applications of telemedicine ...

Abstract	Purpose of review: The purpose of this review is to describe the current state of telemedicine within neuro-oncology. This article will address the development of tele-neuro-oncology over time with a focus on current use and applications of telemedicine within the field. Current modalities and practical considerations for tele-neuro-oncology visits and opportunities for growth will be highlighted. Recent findings: The use of telemedicine has expanded significantly during the COVID-19 pandemic, particularly within neuro-oncology. The use of telemedicine is widely accepted by neuro-oncologic patients and providers and continues to expand in utilization and scope. The use of tele-neuro-oncology is expected to develop further with opportunities for multidisciplinary and integrated care, clinical trials, research, and education. Telemedicine provides a unique, patient-centered approach to neuro-oncologic care. Telehealth will remain a valuable tool, and its use and role are expected to expand within neuro-oncology.
MeSH term(s)	COVID-19/prevention & control ; Humans ; Medical Oncology/methods ; Nervous System Neoplasms/diagnosis ; Nervous System Neoplasms/therapy ; Patient-Centered Care ; SARS-CoV-2 ; Telemedicine/standards ; Telemedicine/trends
Language	English
Publishing date	2022-01-20
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057359-5
ISSN	1534-6269 ; 1523-3790
ISSN (online)	1534-6269
ISSN	1523-3790
DOI	10.1007/s11912-021-01176-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5521: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Medical Complications of Brain Tumors.

Mohile, Nimish A

Continuum (Minneapolis, Minn.)

2017 Volume 23, Issue 6, Neuro-oncology, Page(s) 1635–1652

Abstract: Purpose of review: This article discusses common and emergent medical complications encountered in patients with primary brain tumors.: Recent findings: Clinical studies and systematic reviews published in recent years have improved knowledge ... ...

Abstract	Purpose of review: This article discusses common and emergent medical complications encountered in patients with primary brain tumors. Recent findings: Clinical studies and systematic reviews published in recent years have improved knowledge regarding the incidence of neurologic and medical complications occurring in patients with primary brain tumors. Studies in tumor-related epilepsy and venous thromboembolism provide data for the clinician to make evidence-based decisions about perioperative management, prophylaxis, and therapy. Patients with brain tumors experience unique toxicities related to novel drugs and chemotherapeutics that result in hematologic, infectious, and endocrine disorders. Recent work that has focused on quality of life in patients with brain tumors highlights the importance of good supportive care and optimal medical management of neurobehavioral symptoms and late complications of treatment. Summary: A thorough understanding of the variety of medical and neurologic complications in patients with primary brain tumors improves the clinician's ability to quickly recognize and manage common and urgent conditions.
MeSH term(s)	Antineoplastic Agents/adverse effects ; Brain Neoplasms/complications ; Epilepsy/complications ; Humans ; Quality of Life ; Venous Thromboembolism/complications
Chemical Substances	Antineoplastic Agents
Language	English
Publishing date	2017-12
Publishing country	United States
Document type	Journal Article ; Review
ISSN	1538-6899
ISSN (online)	1538-6899
DOI	10.1212/CON.0000000000000540
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Meet the expert: How I treat chemotherapy-induced peripheral neuropathy.

Wasilewski, Andrea / Mohile, Nimish

Journal of geriatric oncology

2020 Volume 12, Issue 1, Page(s) 1–5

Abstract: Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, often irreversible and disabling adverse effect of many commonly used chemotherapeutic agents. Older patients are at particular risk of developing CIPN due to comorbid conditions affecting ... ...

Abstract	Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, often irreversible and disabling adverse effect of many commonly used chemotherapeutic agents. Older patients are at particular risk of developing CIPN due to comorbid conditions affecting the health of peripheral nerves. Symptoms of CIPN include paresthesias, dysesthesias, sensory loss, motor weakness, dysautonomia, and falls. Pharmacologic management of CIPN involves use of medications including antidepressants, anticonvulsants, and topical treatments for modulation of neuropathic pain. These medications should be used and monitored carefully in older patients as they may increase the risk of confusion, falls, and drug-drug interactions. Patients with CIPN are at an increased risk of falls and should be considered for supportive care interventions including physical and occupational therapy, assistive devices, and safety evaluations. Surveillance of CIPN during and following treatment is essential. The development of neuropathic symptoms may require dose reduction, drug holiday, or transitioning to another chemotherapeutic agent. Symptoms of CIPN typically improve following exposure to neurotoxic therapy, although in older adults the rate of improvement may be slow, and recovery is often incomplete. Early involvement of a neurologist should be considered in patients with atypical, progressive, motor- or autonomic- predominant presentations of neuropathy. Patients with refractory neuropathic pain or those who cannot tolerate standard symptomatic treatment should be referred to a pain specialist or palliative care.
MeSH term(s)	Accidental Falls ; Aged ; Antidepressive Agents ; Antineoplastic Agents/adverse effects ; Humans ; Neuralgia/chemically induced
Chemical Substances	Antidepressive Agents ; Antineoplastic Agents
Language	English
Publishing date	2020-06-17
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	2556813-9
ISSN	1879-4076 ; 1879-4068
ISSN (online)	1879-4076
ISSN	1879-4068
DOI	10.1016/j.jgo.2020.06.008
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: How I treat glioblastoma in older patients.

Mohile, Nimish A

Journal of geriatric oncology

2016 Volume 7, Issue 1, Page(s) 1–6

Abstract: Glioblastoma, a WHO grade IV astrocytoma, is the most common primary malignant brain tumor in adults. It is characterized by molecular heterogeneity and aggressive behavior. Glioblastoma is almost always incurable and most older patients survive less ... ...

Abstract	Glioblastoma, a WHO grade IV astrocytoma, is the most common primary malignant brain tumor in adults. It is characterized by molecular heterogeneity and aggressive behavior. Glioblastoma is almost always incurable and most older patients survive less than 6 months. Supportive care with steroids and anti-epileptic drugs is critical to improving and maintain quality of life. Young age, good performance status and methylation of the methyl guanyl methyl transferase promoter are important positive prognostic factors. Several recent clinical trials suggest that there is a subset of the elderly with prolonged survival that is comparable to younger patients. Treatment of glioblastoma in older patients includes maximal safe resection followed by either radiation, chemotherapy or combined modality therapy. Recent advances suggest that some patients can avoid radiation entirely and be treated with chemotherapy alone. Decisions about therapy are individual and based on a patient's performance status, family support and molecular features. Future work needs to better determine the role for comprehensive geriatric assessments in this patient population to better identify patients who may most benefit from aggressive therapies.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Anticonvulsants/therapeutic use ; Antineoplastic Agents, Alkylating/therapeutic use ; Biomarkers, Tumor/genetics ; Brain Neoplasms/genetics ; Brain Neoplasms/therapy ; Chemoradiotherapy, Adjuvant/methods ; DNA Modification Methylases/genetics ; DNA Repair Enzymes/genetics ; Dacarbazine/analogs & derivatives ; Dacarbazine/therapeutic use ; Geriatric Assessment ; Glioblastoma/genetics ; Glioblastoma/therapy ; Humans ; Isocitrate Dehydrogenase/genetics ; Methylation ; Middle Aged ; Prognosis ; Promoter Regions, Genetic ; Quality of Life ; Seizures/drug therapy ; Standard of Care ; Tumor Suppressor Proteins/genetics
Chemical Substances	Anticonvulsants ; Antineoplastic Agents, Alkylating ; Biomarkers, Tumor ; Tumor Suppressor Proteins ; Dacarbazine (7GR28W0FJI) ; Isocitrate Dehydrogenase (EC 1.1.1.41) ; IDH1 protein, human (EC 1.1.1.42.) ; DNA Modification Methylases (EC 2.1.1.-) ; MGMT protein, human (EC 2.1.1.63) ; DNA Repair Enzymes (EC 6.5.1.-) ; temozolomide (YF1K15M17Y)
Language	English
Publishing date	2016-01
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	2556813-9
ISSN	1879-4076 ; 1879-4068
ISSN (online)	1879-4076
ISSN	1879-4068
DOI	10.1016/j.jgo.2015.12.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Disparities in patient enrollment on glioblastoma clinical trials.

Liu, Yang / Wasilewski, Andrea / Mohile, Nimish A

CNS oncology

2020 Volume 9, Issue 2, Page(s) CNS59

Abstract: Aim: ...

Abstract	Aim:
MeSH term(s)	Adolescent ; Adult ; Age Factors ; Brain Neoplasms/epidemiology ; Brain Neoplasms/therapy ; Clinical Trials as Topic/statistics & numerical data ; Female ; Glioblastoma/epidemiology ; Glioblastoma/therapy ; Health Status Disparities ; Healthcare Disparities/statistics & numerical data ; Humans ; Male ; Middle Aged ; Patient Participation/statistics & numerical data ; Patient Selection ; Randomized Controlled Trials as Topic/statistics & numerical data ; United States/epidemiology ; Young Adult
Language	English
Publishing date	2020-06-30
Publishing country	England
Document type	Journal Article
ZDB-ID	2692808-5
ISSN	2045-0915 ; 2045-0915
ISSN (online)	2045-0915
ISSN	2045-0915
DOI	10.2217/cns-2020-0008
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Durable response to bevacizumab in adults with recurrent pilocytic astrocytoma.

Wasilewski, Andrea / Mohile, Nimish

CNS oncology

2018 Volume 7, Issue 3, Page(s) CNS26

Abstract: Background: Adult pilocytic astrocytomas are rare and highly vascular tumors.: Aim: We hypothesized that they may be uniquely responsive to bevacizumab (BEV).: Patients: We present four adult patients with pathologically diagnosed WHO grade I ... ...

Abstract	Background: Adult pilocytic astrocytomas are rare and highly vascular tumors. Aim: We hypothesized that they may be uniquely responsive to bevacizumab (BEV). Patients: We present four adult patients with pathologically diagnosed WHO grade I pilocytic astrocytoma who had robust and durable responses to BEV at time of recurrence. Three patients developed radiographic changes on MRI, consistent with progressive disease based on response assessment in neuro-oncology criteria. Median time to recurrence was 8.5 months. Methods: All patients were treated with six cycles of BEV for recurrence. Results: At the end of treatment, all patients had achieved a clinical and radiographic response. Median follow-up time after BEV is 20.5 months. Conclusion: This suggests that BEV may have true antitumor activity in adult pilocytic astrocytomas and may be important for achieving durable disease control.
MeSH term(s)	Adult ; Antineoplastic Agents, Immunological/therapeutic use ; Astrocytoma/drug therapy ; Astrocytoma/mortality ; Bevacizumab/therapeutic use ; Brain Neoplasms/drug therapy ; Brain Neoplasms/mortality ; Female ; Humans ; Longitudinal Studies ; Male ; Models, Statistical ; Neoplasm Recurrence, Local/drug therapy ; Survival Analysis ; Survival Rate
Chemical Substances	Antineoplastic Agents, Immunological ; Bevacizumab (2S9ZZM9Q9V)
Language	English
Publishing date	2018-04-09
Publishing country	England
Document type	Journal Article
ISSN	2045-0915
ISSN (online)	2045-0915
DOI	10.2217/cns-2017-0039
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Chemotherapy toxicities and geriatric syndromes in older patients with malignant gliomas.

Wasilewski, Andrea / Alam, Ahmar / Mohile, Nimish

Journal of geriatric oncology

2020 Volume 12, Issue 1, Page(s) 134–138

Abstract: Objective: To describe treatment toxicities and polypharmacy in older patients with malignant gliomas (MG).: Background: Advanced age in cancer patients is associated with increased treatment-related toxicities, acute care utilization and functional ... ...

Abstract	Objective: To describe treatment toxicities and polypharmacy in older patients with malignant gliomas (MG). Background: Advanced age in cancer patients is associated with increased treatment-related toxicities, acute care utilization and functional decline. Most patients with MG are over age 65, yet treatment patterns and toxicities are poorly defined. Methods: A retrospective chart review of 125 patients with MG age 65 or older at the University of Rochester from January 2012 to December 2018. Results: 115 patients with glioblastoma and 10 with anaplastic astrocytoma had a median age of 71 (range 65-89) at diagnosis and median overall survival (OS) of 10.3 months. Radiotherapy (RT) was offered and completed in 79% (fractionated, n = 69, hypofractionated, n = 30). 24% of the 98 patients treated with concurrent temozolomide (TMZ) experienced treatment delays (n = 24). Median of 4 cycles of adjuvant TMZ were taken by 61% (n = 76). Delays and dose reductions occurred in 55% during treatment with adjuvant TMZ, most commonly due to thrombocytopenia (n = 29) and fatigue (n = 15). 16/98 patients required transfusions during treatment with concurrent or adjuvant TMZ. At baseline, patients were prescribed a median of 11 medications. OS was longer in patients prescribed less than 8 medications vs. 8 or more (14 vs. 8.6 months, p = .0738). 96% experienced a non-elective hospital admission and 64% reported at least one fall. Conclusion: Older patients with MG experience significant polypharmacy, treatment toxicities and falls. Studies incorporating geriatric assessment tools may better determine associations between geriatric syndromes and survival. Clinical trials in older patients should also include non-survival outcomes.
MeSH term(s)	Aged ; Antineoplastic Agents, Alkylating/adverse effects ; Brain Neoplasms/drug therapy ; Chemotherapy, Adjuvant ; Dacarbazine/therapeutic use ; Glioblastoma ; Glioma/drug therapy ; Humans ; Retrospective Studies ; Syndrome
Chemical Substances	Antineoplastic Agents, Alkylating ; Dacarbazine (7GR28W0FJI)
Language	English
Publishing date	2020-07-14
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2556813-9
ISSN	1879-4076 ; 1879-4068
ISSN (online)	1879-4076
ISSN	1879-4068
DOI	10.1016/j.jgo.2020.07.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma.

Goldlust, Samuel A / Nabors, Louis B / Hsu, Sigmund / Mohile, Nimish / Duic, Paul J / Benkers, Tara / Singer, Samuel / Rao, Mayank / Cappello, Lori / Silberman, Sandra L / Farmer, George

Neuro-oncology advances

2024 Volume 6, Issue 1, Page(s) vdae009

Abstract: Background: Recurrent glioblastoma (rGBM) has limited treatment options. This phase 1 protocol was designed to study the safety and preliminary efficacy of TPI 287, a central nervous system penetrant microtubule stabilizer, in combination with ... ...

Abstract	Background: Recurrent glioblastoma (rGBM) has limited treatment options. This phase 1 protocol was designed to study the safety and preliminary efficacy of TPI 287, a central nervous system penetrant microtubule stabilizer, in combination with bevacizumab (BEV) for the treatment of rGBM. Methods: GBM patients with up to 2 prior relapses without prior exposure to anti-angiogenic therapy were eligible. A standard 3 + 3 design was utilized to determine the maximum tolerated dose (MTD) of TPI 287. Cohorts received TPI 287 at 140-220 mg/m Results: Twenty-four patients were enrolled at 6 centers. Treatment was generally well tolerated. Fatigue, myelosuppression, and peripheral neuropathy were the most common treatment emergent adverse events. Dose-limiting toxicity was not observed, thus the MTD was not determined. Twenty-three patients were evaluable for median and 6-month progression-free survival, which were 5.5 months (mo) and 40%, respectively. Median and 12-month overall survival were 13.4 mo and 64%, respectively. The optimal phase 2 dose was determined to be 200 mg/m Conclusions: TPI 287 can be safely combined with BEV for the treatment of rGBM and preliminary efficacy supports further investigation of this combination.
Language	English
Publishing date	2024-01-18
Publishing country	England
Document type	Journal Article
ZDB-ID	3009682-0
ISSN	2632-2498 ; 2632-2498
ISSN (online)	2632-2498
ISSN	2632-2498
DOI	10.1093/noajnl/vdae009
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Pilot trial testing the effects of exercise on chemotherapy-induced peripheral neurotoxicity (CIPN) and the interoceptive brain system.

Kleckner, Ian R / Manuweera, Thushini / Lin, Po-Ju / Chung, Kaitlin H / Kleckner, Amber S / Gewandter, Jennifer S / Culakova, Eva / Tivarus, Madalina E / Dunne, Richard F / Loh, Kah Poh / Mohile, Nimish A / Kesler, Shelli R / Mustian, Karen M

Research square

2024

Abstract: Purpose: Chemotherapy-induced peripheral neurotoxicity (CIPN) is a prevalent, dose-limiting, tough-to-treat toxicity involving numbness, tingling, and pain in the extremities with enigmatic pathophysiology. This randomized controlled pilot study ... ...

Abstract	Purpose: Chemotherapy-induced peripheral neurotoxicity (CIPN) is a prevalent, dose-limiting, tough-to-treat toxicity involving numbness, tingling, and pain in the extremities with enigmatic pathophysiology. This randomized controlled pilot study explored the feasibility and preliminary efficacy of exercise during chemotherapy on CIPN and the role of the interoceptive brain system, which processes bodily sensations. Methods: Nineteen patients (65±11 years old, 52% women; cancer type: breast, gastrointestinal, multiple myeloma) starting neurotoxic chemotherapy were randomized to 12 weeks of exercise (home-based, individually tailored, moderate intensity, progressive walking and resistance training) or active control (nutrition education). At pre-, mid-, and post-intervention, we assessed CIPN symptoms (primary clinical outcome: CIPN-20), CIPN signs (tactile sensitivity using monofilaments), and physical function (leg strength). At pre- and post-intervention, we used task-free ("resting") fMRI to assess functional connectivity in the interoceptive brain system, involving the salience and default mode networks. Results: The study was feasible (74-89% complete data across measures) and acceptable (95% retention). We observed moderate/large beneficial effects of exercise on CIPN symptoms (CIPN-20, 0-100 scale: -7.9±5.7, effect size [ES]=-0.9 at mid-intervention; -4.8±7.3, -ES=0.5 at post-intervention), CIPN signs (ES=-1.0 and -0.1), and physical function (ES=0.4 and 0.3). Patients with worse CIPN after neurotoxic chemotherapy had lower functional connectivity within the default mode network (R Conclusion: Exercise during neurotoxic chemotherapy is feasible and may attenuate CIPN symptoms and signs, perhaps via changes in interoceptive brain circuitry. Future work should test for replication with larger samples. ClinicalTrials.gov identifier NCT03021174.
Language	English
Publishing date	2024-03-13
Publishing country	United States
Document type	Preprint
DOI	10.21203/rs.3.rs-4022351/v1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

To top

Full text online

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Inter-library loan at ZB MED